What is the Role of Triglyceride-glucose Index as a Predictive Marker for Insulin Resistance in Pre Diabetic Chronic Kidney Disease Patients?
NCT ID: NCT07279922
Last Updated: 2025-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
60 participants
OBSERVATIONAL
2026-01-01
2028-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Triglyceride/High-density Lipoprotein Cholesterol Ratio in Chronic Kidney Disease
NCT02113462
Hyperuricemia as Early Indication of CKD Progressing in Prediabetic
NCT07199205
Role of Some Biochemical Indices for Prediction of Acute Kidney Injury in Intensive Care Unit Patients in Upper Egypt
NCT06791200
Normoalbuminuric Chronic Kidney Disease in Type 2 Diabetes
NCT04411342
Chronic Kidney Disease in Pregnant Females
NCT06738069
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The triglyceride-glucose (TyG) index, derived from fasting plasma triglycerides and glucose, has recently emerged as a simple, reliable, and cost-effective surrogate marker for insulin resistance. Its utility has been validated in multiple populations, showing strong associations with metabolic dysfunction and future development of diabetes.
Renal dysfunction is frequently associated with alterations in glucose and lipid metabolism, even before overt diabetes develops. However, the diagnostic accuracy of traditional risk markers may be compromised in the context of impaired kidney function. The TyG index offers potential advantages due to its independence from insulin measurements and ease of calculation.
Despite growing evidence on the predictive role of the TyG index, limited data exist regarding its performance across different levels of kidney function. Investigating its diagnostic value in patients with and without renal impairment may provide a valuable tool for early diabetes risk assessment and targeted preventive strategies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triglyceride-glucose index
Triglyceride-glucose index calculation according to TyG index=In\[Triglycerides(mg/dl)×Fasting Glucose(mg/dl)/2\]
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients with medical history free from renal dysfunction
Patients with renal dysfunction (CKD stages 2\_5 based on KDIGO guidelines)
No previous diagnosis of diabetes mellitus
Provided informed consent
Exclusion Criteria
Acute kidney injury
Use of steroids or medications that affect glucose and lipid metabolism
Pregnancy
Active infections
Malignancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eman Osama Ahmed Abd_elsamea
Resident at internal medicine department
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TyG-CKD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.